Valeant Pharmaceuticals CEO Joseph Papa on Wednesday told CNBC he is “never going to say never” to selling core assets like Bausch & Lomb.
“Would we have to look at something if someone came forward with something? Of course we would, because we’re a public company and we have over $30 billion of debt,” he said in an interview with “Closing Bell.”
However, those core assets — like dermatology and eye care — are “critically important” to the future of the company, he added.
